ACTINIUM PHARMACEUTICALS, INC. Operating Lease Cost
ACTINIUM PHARMACEUTICALS, INC. (ATNM) reported Operating Lease Cost of $1.00 thousand for the 3-month period ending 2023-06-30, per its 10-Q filed 2023-08-14.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2023-08-14
- ACTINIUM PHARMACEUTICALS, INC. operating lease, cost for the quarter ending 2023-06-30 was $1.00K, a 95.24% decline year-over-year.
- ACTINIUM PHARMACEUTICALS, INC. operating lease, cost for the quarter ending 2023-03-31 was $2.00K, a 90.48% decline year-over-year.
- ACTINIUM PHARMACEUTICALS, INC. operating lease, cost for the quarter ending 2022-12-31 was $1.00K, a 95.45% decline year-over-year.
- ACTINIUM PHARMACEUTICALS, INC. operating lease, cost for the quarter ending 2022-09-30 was $14.00K, a 36.36% decline year-over-year.
- ACTINIUM PHARMACEUTICALS, INC. operating lease, cost for fiscal 2022 was $57.00K, a 36.67% decline from fiscal 2021.
- ACTINIUM PHARMACEUTICALS, INC. operating lease, cost for fiscal 2021 was $90.00K, a 7.22% decline from fiscal 2020.
- ACTINIUM PHARMACEUTICALS, INC. operating lease, cost for fiscal 2020 was $97.00K.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month |
|---|---|---|---|---|
| 2023-06-30 | $1.00K 10-Q · filed 2023-08-14 | $3.00K 10-Q · filed 2023-08-14 | $4.00K derived: sum of 3 quarters · filed 2023-08-14 | $18.00K derived: sum of 4 quarters · filed 2023-08-14 |
| 2023-03-31 | $2.00K 10-Q · filed 2023-05-15 | $3.00K derived: sum of 2 quarters · filed 2023-05-15 | $17.00K derived: sum of 3 quarters · filed 2023-05-15 | $38.00K derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $15.00K derived: sum of 2 quarters · filed 2023-03-31 | $36.00K derived: sum of 3 quarters · filed 2023-08-14 | $57.00K 10-K · filed 2023-03-31 |
| 2022-09-30 | $14.00K 10-Q · filed 2022-11-14 | $35.00K derived: sum of 2 quarters · filed 2023-08-14 | $56.00K 10-Q · filed 2022-11-14 | $78.00K derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-06-30 | $21.00K 10-Q · filed 2023-08-14 | $43.00K 10-Q · filed 2023-08-14 | $64.00K derived: sum of 3 quarters · filed 2023-08-14 | $86.00K derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $21.00K 10-Q · filed 2023-05-15 | $43.00K derived: sum of 2 quarters · filed 2023-05-15 | $65.00K derived: sum of 3 quarters · filed 2023-05-15 | $88.00K derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | $22.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $44.00K derived: sum of 2 quarters · filed 2023-03-31 | $67.00K derived: sum of 3 quarters · filed 2023-03-31 | $90.00K 10-K · filed 2023-03-31 |
| 2021-09-30 | $22.00K 10-Q · filed 2022-11-14 | $45.00K derived: sum of 2 quarters · filed 2022-11-14 | $68.00K 10-Q · filed 2022-11-14 | $92.00K derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $23.00K 10-Q · filed 2022-08-12 | $46.00K 10-Q · filed 2022-08-12 | $70.00K derived: sum of 3 quarters · filed 2022-08-12 | $94.00K derived: sum of 4 quarters · filed 2022-08-12 |
| 2021-03-31 | $23.00K 10-Q · filed 2022-05-13 | $47.00K derived: sum of 2 quarters · filed 2022-05-13 | $71.00K derived: sum of 3 quarters · filed 2022-05-13 | $96.00K derived: sum of 4 quarters · filed 2022-05-13 |
| 2020-12-31 | $24.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-25 | $48.00K derived: sum of 2 quarters · filed 2022-03-25 | $73.00K derived: sum of 3 quarters · filed 2022-03-25 | $97.00K 10-K · filed 2022-03-25 |
| 2020-09-30 | $24.00K 10-Q · filed 2021-11-12 | $49.00K derived: sum of 2 quarters · filed 2021-11-12 | $73.00K 10-Q · filed 2021-11-12 | |
| 2020-06-30 | $25.00K 10-Q · filed 2021-07-30 | $50.00K 10-Q · filed 2021-07-30 | ||
| 2020-03-31 | $24.00K 10-Q · filed 2021-05-14 | |||
| 2019-09-30 | $26.00K 10-Q · filed 2020-10-23 | $78.00K 10-Q · filed 2020-10-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |